Neovacs S.A. (ALNEV) - Net Assets
Based on the latest financial reports, Neovacs S.A. (ALNEV) has net assets worth €18.89 Million EUR (≈ $22.08 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€23.07 Million ≈ $26.97 Million USD) and total liabilities (€4.18 Million ≈ $4.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Neovacs S.A. liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €18.89 Million |
| % of Total Assets | 81.88% |
| Annual Growth Rate | 13.92% |
| 5-Year Change | 64.5% |
| 10-Year Change | 197.65% |
| Growth Volatility | 127.87 |
Neovacs S.A. - Net Assets Trend (2007–2024)
This chart illustrates how Neovacs S.A.'s net assets have evolved over time, based on quarterly financial data. Also explore Neovacs S.A. (ALNEV) total assets for the complete picture of this company's asset base.
Annual Net Assets for Neovacs S.A. (2007–2024)
The table below shows the annual net assets of Neovacs S.A. from 2007 to 2024. For live valuation and market cap data, see ALNEV stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €18.06 Million ≈ $21.12 Million |
-58.78% |
| 2023-12-31 | €43.82 Million ≈ $51.23 Million |
-0.93% |
| 2022-12-31 | €44.23 Million ≈ $51.71 Million |
+0.76% |
| 2021-12-31 | €43.90 Million ≈ $51.32 Million |
+299.80% |
| 2020-12-31 | €10.98 Million ≈ $12.84 Million |
+301.05% |
| 2019-12-31 | €2.74 Million ≈ $3.20 Million |
+12.36% |
| 2018-12-31 | €2.44 Million ≈ $2.85 Million |
+188.11% |
| 2017-12-31 | €845.75K ≈ $988.77K |
-32.64% |
| 2016-12-31 | €1.26 Million ≈ $1.47 Million |
-79.31% |
| 2015-12-31 | €6.07 Million ≈ $7.09 Million |
+9.00% |
| 2014-12-31 | €5.57 Million ≈ $6.51 Million |
+59.99% |
| 2013-12-31 | €3.48 Million ≈ $4.07 Million |
-3.88% |
| 2012-12-31 | €3.62 Million ≈ $4.23 Million |
-65.75% |
| 2011-12-31 | €10.57 Million ≈ $12.36 Million |
+27.73% |
| 2010-12-31 | €8.27 Million ≈ $9.67 Million |
+2446.72% |
| 2009-12-31 | €-352.58K ≈ $-412.20K |
-105.41% |
| 2008-12-31 | €6.51 Million ≈ $7.61 Million |
+230.56% |
| 2007-12-31 | €1.97 Million ≈ $2.30 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Neovacs S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4640452500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €174.51K | 0.97% |
| Other Comprehensive Income | €782.47K | 4.33% |
| Other Components | €77.44 Million | 428.74% |
| Total Equity | €18.06 Million | 100.00% |
Neovacs S.A. Competitors by Market Cap
The table below lists competitors of Neovacs S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Peak Processing Limited
AU:PKP
|
$116.06 |
|
CuriosityStream Inc
NASDAQ:CURIW
|
$119.51 |
|
Adheris Health Limited
AU:AHE
|
$136.79 |
|
PetroFrontier Corp
V:PFC
|
$143.16 |
|
NRx Pharmaceuticals Inc
NASDAQ:NRXPW
|
$111.30 |
|
Tarrina Resources Limited
AU:TR8
|
$110.79 |
|
Versus Systems Inc
NASDAQ:VSSYW
|
$109.94 |
|
European Resources Limited
AU:ERE
|
$98.85 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neovacs S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 43,821,471 to 18,062,164, a change of -25,759,307 (-58.8%).
- Net loss of 32,914,409 reduced equity.
- Share repurchases of 2,132,030 reduced equity.
- New share issuances of 2,132,027 increased equity.
- Other comprehensive income decreased equity by 507,450.
- Other factors increased equity by 7,662,555.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-32.91 Million | -182.23% |
| Share Repurchases | €2.13 Million | -11.8% |
| Share Issuances | €2.13 Million | +11.8% |
| Other Comprehensive Income | €-507.45K | -2.81% |
| Other Changes | €7.66 Million | +42.42% |
| Total Change | €- | -58.78% |
Book Value vs Market Value Analysis
This analysis compares Neovacs S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | €-1612883.00 | €0.00 | x |
| 2010-12-31 | €6079522.00 | €0.00 | x |
| 2011-12-31 | €4767.07 | €0.00 | x |
| 2012-12-31 | €566.44 | €0.00 | x |
| 2013-12-31 | €190.29 | €0.00 | x |
| 2014-12-31 | €1047.81 | €0.00 | x |
| 2015-12-31 | €1839.95 | €0.00 | x |
| 2016-12-31 | €1255546.00 | €0.00 | x |
| 2017-12-31 | €845746.00 | €0.00 | x |
| 2018-12-31 | €2436704.00 | €0.00 | x |
| 2019-12-31 | €1368954.50 | €0.00 | x |
| 2020-12-31 | €1372532.88 | €0.00 | x |
| 2021-12-31 | €176301.97 | €0.00 | x |
| 2022-12-31 | €14.66 | €0.00 | x |
| 2023-12-31 | €1245990.08 | €0.00 | x |
| 2024-12-31 | €103.50 | €0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neovacs S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -182.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8984.51%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.22x
- Recent ROE (-182.23%) is above the historical average (-412.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -284.69% | -3748.10% | 0.03x | 2.40x | €-4.92 Million |
| 2008 | -87.71% | -8519.86% | 0.01x | 1.65x | €-5.16 Million |
| 2009 | 0.00% | -1861.36% | 0.08x | 0.00x | €-6.73 Million |
| 2010 | -147.76% | -52466.34% | 0.00x | 1.76x | €-9.59 Million |
| 2011 | -102.85% | -106.68% | 0.59x | 1.65x | €-8.90 Million |
| 2012 | -759.50% | -35750845.00% | 0.00x | 6.60x | €-7.24 Million |
| 2013 | -1778.43% | -22997.13% | 0.00x | 19.85x | €-6.91 Million |
| 2014 | -303.69% | -5297.32% | 0.02x | 3.66x | €-7.76 Million |
| 2015 | -77.17% | -3166.39% | 0.01x | 1.85x | €-5.29 Million |
| 2016 | -1109.67% | -90312.20% | 0.00x | 7.43x | €-14.06 Million |
| 2017 | -1754.48% | -115618.20% | 0.00x | 13.80x | €-14.92 Million |
| 2018 | -442.40% | -7434.48% | 0.02x | 2.97x | €-11.02 Million |
| 2019 | -275.69% | -7932.63% | 0.01x | 2.75x | €-7.82 Million |
| 2020 | -55.94% | -20624.03% | 0.00x | 1.23x | €-7.24 Million |
| 2021 | -26.96% | -52389.03% | 0.00x | 1.11x | €-16.23 Million |
| 2022 | -8.02% | -319109.98% | 0.00x | 1.11x | €-7.97 Million |
| 2023 | -19.95% | -1639.16% | 0.01x | 1.08x | €-13.13 Million |
| 2024 | -182.23% | -8984.51% | 0.02x | 1.22x | €-34.72 Million |
Industry Comparison
This section compares Neovacs S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $37,043,996
- Average return on equity (ROE) among peers: -24.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neovacs S.A. (ALNEV) | €18.89 Million | -284.69% | 0.22x | $111.44 |
| Abionyx Pharma SA (ABNX) | $6.63 Million | -28.45% | 0.55x | $123.48 Million |
| Abivax SA (ABVX) | $33.94 Million | -14.97% | 0.12x | $6.97 Billion |
| Adocia (ADOC) | $-12.97 Million | 0.00% | 0.00x | $109.57 Million |
| Aelis Farma SA (AELIS) | $19.79 Million | -72.20% | 0.98x | $18.95 Million |
| Biophytis S.A. (ALBPS) | $-3.89 Million | 0.00% | 0.00x | $1.03 Million |
| Cellectis (ALCLS) | $308.85 Million | -23.50% | 0.52x | $271.40 Million |
| Advicenne (ALDVI) | $1.81 Million | -109.74% | 0.78x | $14.80 Million |
| Genoway (ALGEN) | $16.17 Million | 4.81% | 1.04x | $30.11 Million |
| Integragen (ALINT) | $2.20 Million | -0.16% | 3.10x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-2.08 Million | 0.00% | 0.00x | $1.80 Million |
About Neovacs S.A.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IF… Read more